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Diabetes mellitus is a chronic disease that necessitates continuing treatment and patient self-care education.
Monitoring of blood glucose to near normal level without hypoglycemia becomes a challenge in the management
of diabetes. Although self monitoring of blood glucose (SMBG) can provide daily monitoring of blood glucose level
and help to adjust therapy, it cannot detect hypoglycemic unawareness and nocturnal hypoglycemia which
occurred mostly in T1DM pediatrics. Continuous glucose monitoring (CGM) offers continuous glucose data every
5 minutes to adjust insulin therapy especially for T1DM patients and to monitor lifestyle intervention especially for
T2DM patients by care providers or even patients themselves. The main objective of this study was to assess the
effects of continuous glucose monitoring (CGM) on glycemic control in Type 1 diabetic pediatrics and Type 2
diabetic adults by collecting randomized controlled trials from MEDLINE (pubmed), SCOPUS, CINAHL, Web of
Science and The Cochrane Library up to May 2013 and historical search through the reference lists of relevant
articles. There are two types of CGM device: real-time CGM and retrospective CGM and both types of the device
were included in the analysis. In T1DM pediatrics, CGM use was no more effective than SMBG in reducing HbA1c
[mean difference – 0.13% (95% CI -0.38% to 0.11%,]. This effect was independent of HbA1c level at baseline.
Subgroup analysis indicated that retrospective CGM was not superior to SMBG [mean difference -0.05% (95%
CI -0.46% to 0.35%)]. In contrast, real-time CGM revealed better effect in lowering HbA1c level compared with
SMBG [mean difference -0.18% (95% CI -0.35% to -0.02%, p = 0.02)]. In T2DM adults, significant reduction in HbA1c
level was detected with CGM compared with SMBG [mean difference – 0.31% (95% CI -0.6% to -0.02%, p = 0.04)].
This systematic review and meta-analysis suggested that real-time CGM can be more effective than SMBG in T1DM
pediatrics, though retrospective CGM was not. CGM provided better glycemic control in T2DM adults compared
with SMBG.
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The global prevalence of diabetes by International Dia-
betes Federation (IDF) estimation shows that there are
366 million people with diabetes in 2011, and this is
expected to rise to 552 million by 2030 [1]. Diabetes
caused 4.6 million deaths in 2011 [2]. Most of people
afflicted with diabetes (85 – 95%) have type 2 diabetes
mellitus [3]. Forty-four percent of people with type 2* Correspondence: naeti.suk@mahidol.ac.th
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reproduction in any medium, provided the ordiabetes show hemoglobin A1C higher than the gener-
ally accepted target [4]. Recent studies have established
that improved glycemic control by means of intensive
diabetes management decreases the risk of long-term
microvascular complications in both type 1 and type 2
diabetic patients [5]. However, the major problem with
an intensive diabetes treatment is the increased risk of
hypoglycemic events. Subjects in the intensive manage-
ment group of the Diabetes Control and Complications
Trial (DCCT) experienced severe hypoglycemia two to
three times more often than subjects receiving conven-
tional therapy [6]. The fear of hypoglycemia often leadsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complications resulting in loss of control and cognitive
dysfunction [7]. Therefore, in addition to intensive treat-
ment, self management of blood glucose to normal or
within normal limits is a crucial aspect.
Self monitoring of blood glucose (SMBG) has been
shown to be as effective in insulin-treated type 1 and
type 2 diabetes. Although the effect of SMBG already
demonstrated in some meta-analysis [8,9], it is
not recommended as regularly use in non-insulin treated
type 2 diabetes. SMBG fails to detect nocturnal
hypoglycemia and asymptomatic hypoglycemia even in
patients with good control of HbA1c values and it needs
multiple blood samples throughout the day. In addition,
SMBG gives a single instant reading without any infor-
mation on glucose trends and thus may miss important
and significant glucose fluctuations [10-12]. Continuous
glucose monitoring (CGM) measures interstitial fluid
every 10 seconds and an average glucose value is
recorded every five minutes 24 hours a day. This gives a
more accurate pattern of daily glucose fluctuations
allowing identification of the glycemic effect of food,
physical activity, insulin and different medication types
and doses aiding in better self management with
avoiding unrecognized hypoglycemia [13].
Although some randomized trials show the benefit of
CGM use over SMBG in type 1 diabetic pediatric popu-
lation [14,15], previous meta-analysis on type 1 diabetic
pediatric patients failed to show the effectiveness of
CGM on the decline of HbA1c level compared with
SMBG [16], further evidence is still needed to provide
effectiveness of CGM on pediatric type 1 diabetic popu-
lation. Only one meta-analysis reported that the effect-
iveness of CGM on type 2 diabetic patients was superior
to SMBG use [17]. However, the strength of evidence of
reducing HbA1c in that population is limited because
the number of patients in the included studies was ra-
ther low. In our meta-analysis, the effectiveness of CGM
use over SMBG was evaluated in Type 1 diabetic
pediatrics and Type 2 diabetic adults to provide a com-
prehensive and quantitative synthesis of evidence from
all randomized controlled trials (RCTs) and to make




Reports of randomized controlled trials of CGM aimed
for good glycemic control in type 1 diabetic and type 2
diabetic patients are identified through a systematic lit-
erature search of MEDLINE (Pubmed), Scopus,
CINAHL, Web of Science and The Cochrane Library.
The bibliographic databases were searched from the in-
ception to May 2013. The following MeSH terms wereused; diabetes mellitus and continuous glucose monitor-
ing. This was followed by keyword search using as key-
words continuous monitoring of blood glucose, CGM,
insulin-dependent diabetes mellitus, IDDM, non-insulin
dependent diabetes mellitus and NIDDM. Historical
search of reference lists of relevant randomized con-
trolled trials, systematic and narrative reviews was also
undertaken. No language restriction was imposed.
Inclusion criteria and exclusion criteria
To be included in the systematic review, studies had to
be
a) randomized controlled trials comparing currently
available CGM device with SMBG in patients with
type 1 diabetes pediatrics (≤ 18 yrs) or type 2
diabetes adults (≥ 18 yrs),
b) of at least 8 weeks duration, and
c) reporting HbA1c as an outcome measure.
We excluded studies involving
a) pregnant women,
b) critically ill patients, post-surgery, post-transplant
and ICU patients.
Data extraction and study quality assessment
Data from individual studies were abstracted and study
quality was evaluated independently by two authors
using a standardized form. The disagreements were re-
solved by a third author. The methodological quality of
each study was assessed using Maastricht Amsterdam
scale [18], which has been developed based on the scale
of Jadad et al [19] and the Delphi list [20]. These 12
items evaluated the internal validity of the study results.
Each item had a rating scale of “yes,” “no,” or “unsure.”
If bias was unlikely, the item was rated positive. If bias
was likely, the item was rated as negative. Then, if infor-
mation concerning the item was not available, it was
rated with “unsure.” Out of 12 items, only 11 items were
used to assess the quality of studies because one item
that investigates patient compliance is not applicable to
CGM intervention. Studies that met at least 6 of 11
quality criteria were of high quality. Those scoring less
than 6 of the criteria were of low quality or having high
risk of bias.
Statistical analysis
Outcome of interest was HbA1c. Treatment effect was
estimated with mean difference in the final values of
HbA1c between the CGM group and the SMBG group.
In a randomized trial, a comparison of final measure-
ment can usually be assumed to provide the same esti-
mate as the comparison of changes from baseline.
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of individual studies when Q-statistic test was significant
at the level of 0.1, otherwise the fixed effects model was
used. Heterogeneity was also determined by I2. Substan-
tial heterogeneity was represented by I2 of 50% or more
[21]. Subgroup analysis was carried out based on the
data presentation of CGM device [real-time (RT) CGM
and retrospective (r) CGM] and study quality. Moreover,
subgroup analysis based on baseline HbA1c level (< 8%,
8-10%, and >10%) was also performed to assess the im-
pact of baseline HbA1c level on the effectiveness of
CGM. Sensitivity analysis was conducted by excluding
studies reporting lower number of usable CGM data.
The statistical analysis was undertaken with Review
Manager (Revman®) program version 5.2.3 (Cochrance
collaboration, Oxford UK). A funnel plot and Egger re-
gression test [22] were used to assess publication bias.
Results
Study characteristics
In pediatric Type 1 diabetes, ten RCTs involving 817
participants met our predefined inclusion criteria. The
diagram of data extraction is illustrated in Figure 1. The
characteristics of included trials are summarized in
Table 1. Seven studies are regarded as high quality
[14,15,23-27] and three studies are regarded as low qual-
ity [28-30]. Retrospective CGM (r-CGM) was used in 5
studies [23-25,28,29] and Real-Time CGM (RT-CGM)
was used in 5 studies [14,15,26,27,30]. Duration of study
of all trials ranged from 3 months to 12 months. Five
studies [24-26,28,30] included participants with insulin
pump therapy or insulin injection therapy, three studies
[14,23,29] included only participants with insulin injec-
tion therapy and two studies [15,27] included only par-
ticipants with insulin pump therapy. Among ten studies,MEDLINE, SCOPUS, CINAHL, Web of 
Science and The Cochrane Library, 
Historical search 
Total of 436 clinical trials screened 
40 RCTs retrieved 
396 trials excluded: Not 
randomized controlled trials 
Excluded (n=30):  Pregnanc
group, Mixed population (T1
GlucoWatch biographer use
Figure 1 Summary of trial flow (Type 1 diabetic pediatrics).four studies were multi-centered [14,15,26,27]. There
were two single-blinded studies [24,30] and one double-
blinded study [23]. Two out of ten studies were cross-
over randomized trials [15,23].
In Type 2 diabetes, five RCTs involving 161 partici-
pants met our predefined inclusion criteria [31-35]. The
diagram of data extraction is illustrated in Figure 2.
Among these 5 trials, there was a study which analyzed
separately for two follow-up periods; i.e, 26 weeks and
52 weeks, and presented the results in two separated pa-
pers [34,35]. Only the paper with intervention period
was included in the analysis [34]. Therefore, only 4 ran-
domized trials were included in meta-analysis. The char-
acteristics of included trials are summarized in Table 2.
Two studies were of high quality [31,33] and other two
studies were of low quality [32,34]. Among 4 trials, only
one trial is multi-centered study [32]. One study was
conducted to test the effects of a counseling intervention
using continuous glucose monitoring system feedback
on physical activity self-efficacy and reported HbA1c as
a secondary outcome [33]. Two studies were performed
in T2DM patients who were not treated with insulin
[33,34] and other two included participants treated with
either oral hypoglycemic agents (OHA) or insulin injec-
tions [31,32].
Type 1 diabetic pediatrics
Total analysis
There were a total of 817 type 1 diabetic pediatrics (413
in CGM group and 404 in SMBG group) in ten trials
that compared CGM use with SMBG. Significant hetero-
geneity was found among the study results. The reason
may be because of variations in patients’ characteristics,
intervention used, pattern and frequency of CGM use,
and quality of studies. The use of CGM did not provide10 randomized trials 
(14,15,23-30) 
y, Mixed age 
DM and T2DM) 
d 
Table 1 Characteristics of included studies in Type 1 diabetic pediatrics
Study Country Duration N Intervention CGM Use SMBG Use Main Outcomes
Chase [28] USA 3 months 11 The MiniMed CGM
vs. SMBG
18 total sensor days within 30- day
(total 6 times) + 4 times SMBG tests
Minimum of 4 daily SMBG
tests
• HbA1c
I:5 • Number of
hypoglycemic events
C:6 • Number of insulin
dosage changes
• Fear of hypoglycemia
Deiss [23] Germany 3 months 30 The MiniMed CGM
vs. SMBG
3 days of CGM every 6 weeks over 12
weeks. (total 2 times) (once open,
once blinded) + at least 5 times SMBG
tests
At least 5 times per day • HbA1c
I:15
C:15
Lagarde [24] USA 6 months 27 RT-CGM vs. SMBG 3 days of CGM (Open) every 2
months. (total 3 times) +Usual practice
of monitoring BG
3 days of CGM (Blinded) at
0,2, and 4 months +
• HbA1c
I:18 • AUC for glucose
< 70 mg/dL
C:9 Usual practice of monitoring
BG
• Duration and severity
of hypoglycemia
before meals, at bedtime and at 2:00
hours once weekly.
before meals, at bedtime and
at 2:00 hours once weekly.
Yates [25] Australia 3 months 36 The MiniMed
CGMvs.SMBG
3 days of CGM every 3 weeks over 3
months (total 4 times) + at least 4
times SMBG
4 to 6 times daily • HbA1c
I: 19 • Fructosamine
C:17
JDRF [26] England 26 weeks 114 CGMS Use the device on a daily basis +
4times SMBG






• The amount of time
in hypoglycemic and
hyperglycemic per day
C:58 • relative reduction of
10% or more in the
mean glycated
hemoglobin level





1-week period/ 6 months + SMBG Sensor glucose values are
collected for 1 week periods
at Baseline, 6 months and 1
years (Not Display data)
• HbA1c
I: 78 • Severe rates of
hypoglycemia
C: 78
Kondonouri [27] France 12 months 154 CGM (MiniMed
paradigm) vs.
SMBG
Use on a daily basis, replace the
sensors every 3 days + SMBG (at least
4 times/day)























Table 1 Characteristics of included studies in Type 1 diabetic pediatrics (Continued)
Battelino [15] Slovenia 6 month 72 CGM (Guardian
REAL-Time) vs.
SMBG
Used on a daily basis + SMBG SMBG • HbA1c
I/C:37 • Changes in glycaemic
patterns






BosniaHerzegovina 6 months 80 CGM (Medtronic
Minimed) vs. SMBG
3 days of CGM (only one time) + at
least 4 daily SMBG (before and after
each main meal, at bedtime and
during the night at 2 a.m and 5 a.m)
At least 4 daily SMBG (before
and after each main meal, at
bedtime and during the
night at 2 a.m and 5 a.m)
• HbA1c
I: 40 • Average SMBG values
C: 40 • Numbers of hypo-
and hyperglycemic
events.
Mauras [30] USA 26 weeks 137 CGM (FreeStyle
Navigator) vs.
Usual care
Use CGM on a daily basis (Open) + ≥
4 times SMBG
Use CGM on a daily basis
(Blinded) + ≥ 4 times SMBG
• Decrease in HbA1c of
≥ 0.5% from baseline




Abbreviations: AUC area under the curve, BG blood glucose, CGM continuous glucose monitoring, HbA1c Hemoglobin A1c, JDRF Juvenile Diabetes Research Foundation, MDI multiple daily injection, RT-CGM real-time





















MEDLINE, SCOPUS, CINAHL, Web of 
Science and The Cochrane Library, Historical  
search 
Total of 212 clinical trials screened 
23 RCTs retrieved 
188 trials excluded: Not  
randomized controlled trials 
Excluded (n=19):  Pregnancy, Mixed age group, 
Mixed population (T1DM and T2DM) .Did not test 
the benefit of CGM. Follow-up report 
4 randomized trials  
(31-34) 
Figure 2 Summary of trial flow (Type 2 diabetic adults).
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tion in T1DM pediatrics. The pooled estimate of HbA1c
difference was – 0.13% (95%CI -0.38% to 0.11%,
p = 0.27) (Figure 3). Publication bias was detected
(Egger: bias = -3.19 (95% CI = -6.35 to -.028) P = 0.048
(Figure 4).
Subgroup analysis based on type of data presentation
Retrospective CGM vs. SMBG
Retrospective CGM (r-CGM) was used in 5 trials
[23-25,28,29]. The r-CGM was no better than SMBG
use for glycemic control in T1DM pediatrics. The
pooled mean difference in HbA1c was -0.05% (95% CI -
0.46% to 0.35%, p = 0.79) (Figure 5).
Real-time CGM vs. SMBG
Real time CGM (RT-CGM) was used in 5 trials
[14,15,26,27,30]. The use of RT-CGM was superior to
the usual care in improving glycemic control. The
pooled mean difference in HbA1c was -0.18% (95% CI -
0.35% to -0.02%, p = 0.02) (Figure 6).
Subgroup analysis based on HbA1c at baseline
Subgroup analysis was also performed according to
baseline HbA1c of participants in the studies (HbA1c <
8%, HbA1c 8-10%, HbA1c > 10%). There were 2 studies
with HbA1c at baseline < 8%. The results suggested that
CGM was no more effective than SMBG in glycemic
control regardless of baseline HbA1c level. The pooled
mean difference in HbA1c was -0.01% (95%CI -0.23% to
0.20%, p = 0.91), -0.19% (95%CI -0.61% to 0.23%,
p = 0.38) and -0.23% (95%CI -0.58% to 0.13%, p = 0.21),
respectively, for baseline HbA1c < 8%, 8-10%, and > 10%
(Figure 7).Subgroup analysis based on quality of included studies
Subgroup analysis was also performed according to qual-
ity of studies (high quality studies and low quality
studies). There were 7 high quality studies and 3 low
quality studies. The pooled mean difference in HbA1c
was -0.25% (95%CI -0.57% to 0.07%, p = 0.12) for high
quality studies and 0.18% (95%CI -0.16% to 0.52%, p =
0.30) for studies with low quality (Figure 8).
Sensitivity analysis
Sensitivity analysis was performed by excluding two
studies which described lower number of usable CGM
data [25,28]. For example, one study reported that only
70% of the total hours worn was usable and this subopti-
mal data was because of insufficient calibration points
[25], while the other described that the lower numbers
of usable CGM data was available because of patient
noncompliance [28]. Participants in Chase et al. study
[28] attained an average of less than 50% (421 of 864
possible) usable readings per sensor. We have doubted
that whether this percentage of data would represent the
overall effect on experimental population. Enough ex-
planation for usable data was not provided in individual
study and there are no criteria to identify the amount of
the CGM data to represent the experimental group.
Therefore, this may bias the result in favor of SMBG.
Heterogeneity was reduced from 71% to 35% when these
two trials were excluded. Glycemic control was better
with CGM than SMBG (mean difference -0.23%, 95% CI
-0.38% to -0.08%, p = 0.003) (Figure not shown).
Type 2 diabetic adults
There were a total of 228 type 2 diabetic adults (111 in
the intervention group and 117 in the control group) in
four trials that compared CGM use with SMBG. The use
Table 2 Characteristics of included studies in Type 2 diabetic adults
Study Country Duration n Intervention CGM Use SMBG Use Outcomes




RT-CGM occurred in four cycles (2 weeks on/1 week
off) for 3 months + SMBG before meals, at bedtime
and at the time of hypo- or hyperglycemia
SMBG before meals and at bedtime, at the time
of hypo- or hyperglycemia
• A1C





• Diabetes – related stress




48 hour of CGM at baseline and after 3 months +
usual SMBG
Usual SMBG • A1C
• Compare the 48 h CGM
data at baseline with those






Allen [33] USA 8 weeks 46 RT-CGM vs.
SMBG
72 hour of CGM + SMBG SMBG • Physical activity self
efficacy
I:21
C:25 • Physical activity levels
• Blood pressure
• Body mass index
• A1C
Yoo [31] Korea 3 months 57 RT-CGM
(Guardian RT)
vs. SMBG
Once a month for 3 day for 12 weeks + at least three
SMBG per day
SMBG at least four times a week, including
fasting blood glucose and postprandial 2 h
blood glucose levels for 3 months continuously
• A1C
I: 29 • Fasting blood glucose





• Body mass index





















Figure 3 Mean difference (95% confidence interval) in HbA1c for CGM versus SMBG in T1DM pediatrics.
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terms of HbA1c reduction in T2DM adults. The pooled
mean difference in HbA1c was – 0.31% (95%CI -0.6%
to -0.02%, p = 0.04) (Figure 9). No publication bias was
detected (Egger: bias = 0.29, 95% CI = -1.77 to 2.36)
(Figure not shown).
Discussion
Type 1 diabetic pediatrics
According to American Academy of Pediatrics, the term
‘pediatric’ includes population from birth to 18 years old
[36]. In our meta-analysis, we then used the term
‘pediatric’ and included studies with T1DM participant ≤
18 years of age. The principal meta-analysis evaluated
the effect of both retrospective CGM and real-time
CGM altogether and included 10 randomized controlled
trials. The pooled results revealed that as a whole CGMFigure 4 Funnel plot for ten randomized controlled trials of CGM verwas no more effective than SMBG in lowering HbA1c
[mean difference -0.13%, 95%CI -0.38% to 0.11%). The
results support the conclusion previously reported by
Golicki et al (mean difference -0.02%, 95%CI -0.29 to
0.25) [16]. Their meta-analysis of CGM in children in-
cluded five studies from the age of 2 to 19 years [16].
Our meta-analysis included ten studies, four of which
already included in their meta-analysis. One study that
was included in the previous meta-analysis was excluded
from ours because participants were older than 18 years
[37]. Although study participants aged < 18 years were
eligible, those aged 2-18 years were enrolled among the
trials contributed to our meta-analysis since there was
no randomized study on participants with age ≤ 2 years.
In addition, their meta-analysis limited to only one de-
vice, Metronic MiniMed. In contrast, our meta-analysis
included all kinds of CGM devices which are available insus SMBG in T1DM pediatrics.
Figure 5 Mean difference (95% confidence interval) in HbA1c for retrospective CGM versus SMBG in T1DM pediatrics.
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our study was to investigate a treatment strategy using
CGM technology and not a specific device.
Inconsistency among studies as assessed by I2 statistic
was statistically significant (I2 = 71%). There was differ-
ence in sample size among studies ranging from 11 to
156 participants. Other possible reasons for heterogen-
eity may be the differences in frequency and duration of
CGM use, intervention period, and intervention used
among those studies (retrospective or real-time CGM
studies). In all studies with retrospective CGM, the de-
vice was used for 72 consecutive hours but with different
frequency for different duration, for example, 6 times
in 1 month [28], 1 time in 3 months [29], 4 times in
3 months [25], 3 times in 4 months [24], and 1 time in
3 months [23]. For RT-CGM, the device was used on a
daily basis except in the study by Bergenstal et al. [14] in
which the device was used for 1-week period continu-
ously per 6 months. Subgroup analysis based on the fre-
quency of CGM use was not possible. In addition,
various types of insulin delivery systems were employed
among individual trials, for example, both insulin pump
and insulin injection therapies [24-26,28,30], insulin in-
jection alone [14,23,29], and insulin pump therapy alone
[15,17].
It has been demonstrated that patients who used
CGM devices had a greater decrease in hemoglobin A1c
from baseline compared with those using SMBG in type
1 diabetics patients [mean difference – 0.26% (95%CI -0
.34% to -0.19%)]. However, when the effectiveness of theFigure 6 Mean difference (95% confidence interval) in HbA1c for realr-CGM and RT-CGM compared with SMBG were ana-
lyzed separately, only RT-devices for CGM improved
glycemic control [mean difference -0.27% (95%CI-0.34%
to -0.19%)] [38]. The beneficial effect of RT- CGM over
SMBG was consistently described in type 1 pediatric
population [39]. Other meta-analysis of CGM in
pediatric population also reported no significant effect of
r- CGM compared with SMBG [16]. Therefore, although
RT-CGM gave profound benefit to type 1 diabetic popu-
lation, the value of r-CGM was somewhat limited. These
results are subsequently confirmed by our meta-analysis,
showing that as a whole CGM did not provide better
benefit over SMBG. Specifically, glycemic control was
better with RT-time CGM compared with SMBG [mean
difference -0.18% (95% CI -0.35% to -0.02%, p = 0.02)],
whereas it was no better with r-CGM than with SMBG
[mean difference -0.05% (95% CI -0.46% to 0.35%)]. As a
matter of fact, regarding patient perspective, learning
about the application of device can be a burden to pa-
tients in using RT-CGM. R-CGM seems to be more con-
venient since patients need doing nothing. However, RT-
CGM proved better glycemic control than r-CGM. For
r-CGM, physicians or care providers can adjust therapy
based on CGM data. For RT-CGM, physicians make
therapeutic adjustment based on CGM data and, at the
same time, patients can also monitor lifestyle interven-
tion themselves. In other words, RT-CGM can be a sup-
portive tool for both pharmacological intervention and
lifestyle intervention. This contributes to better glycemic
control compared with r-CGM.-time CGM versus SMBG in T1DM pediatrics.
Figure 7 Mean difference (95% confidence interval) in HbA1c for CGM versus SMBG according to HbA1c at baseline in
T1DM pediatrics.
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glucose-lowering therapies is baseline HbA1c, as higher
baseline HbA1c is associated with greater reductions in
HbA1c [40] if tightly controlled. Regarding the effect of
SMBG, glycemic control significantly improved in pa-
tients whose baseline HbA1c was ≥ 8% [9]. The impact
of baseline HbA1c on the effect of CGM in lowering
glucose level has never been evaluated yet. In our meta-
analysis, participants from the included studies had var-
ied baseline HbA1c level. Diabetes Center and Joslin
Clinic made a clinical recommendation that intensive
therapy is need if HbA1c is > 8% [41]. Moreover, signifi-
cant high risk of microvascular complications was found
in subjects with poor glycemic control (HbA1c > 8%)
[42]. Therefore, we used HbA1c level of 8% as a cutoff
point and the analysis was stratified into three subgroups
of baseline HbA1c: <8%, 8 - 10% and > 10%. It was found
that CGM was not effective in improving glycemic con-
trol regardless of baseline HbA1c. Moreover, subgroup
analysis by quality of studies was performed to analyze
the effect of study quality on heterogeneity and it was
found that quality of studies had no impact on
heterogeneity.
The Juvenile Diabetes Research Foundation primary
study which compared RT- CGM with SMBG in threeage groups (8-14 years, 15 – 24 years and ≥ 25 years)
found that CGM was only significantly more effective
than SMBG in those aged 25 or more, most likely be-
cause older patients used the sensor more frequently
since it was found that sensor use was significantly
greater in ≥ 25 age group than ≤ 25 age groups (p <
0.001) [26]. The important point related with this finding
may be independent of sensor use; older patients are
slightly more able than younger patients to interpret
data from continuous glucose monitoring to adjust ther-
apy and lifestyle intervention to maintain good glycemic
control. To attain better glycemic control in pediatric
population, co-operation of parents is demanded. Poor
adherence in diabetes management has been recognized
as a hindrance to get successful glycemic control in ado-
lescents and children with type 1 diabetes. Moreover, the
transition from parental assistance with management of
diabetes to patient-only management is often associated
with deterioration of glycemic control [43,44]. According
to those findings, RT- CGM can be a useful tool in gly-
cemic control for T1DM pediatric population if the par-
ents and children are carefully educated about the
application and benefit of the device. Among 5 RT-CGM
studies included in our meta-analysis, only one study in-
dicated that both patients and their parents were
Figure 8 Mean difference (95% confidence interval) in HbA1c for CGM versus SMBG according to quality of included studies in
T1DM pediatrics.
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patients were educated in the remaining four studies.
Better results from RT-CGM devices can be expected
when not only patients but also their parents are care-
fully educated about the effect of device on therapy.
Apart from substantial heterogeneity among study
results as previously discussed, the limitation of meta-
analysis in T1DM pediatrics was the presence of publi-
cation bias since only published trials were included.
This may lead to omitting appropriate data for the ana-
lysis. Other than publication bias, plot asymmetry may
be due to small study effect; i.e, the association between
estimated intervention effect and the sample size is
much different from those might be expected by chance.
Consequently, false positive results can be brought about
by small studies. In our meta-analysis, we suspected
small study effect to be contributed by one study in
which the sample size was too small (n = 11) [28]. The
effective appropriate frequency and duration of CGMFigure 9 Mean difference (95% confidence interval) in HbA1c for CGMuse is also a good point to focus in further studies. In
addition, it would be worth analyzing the benefit of
CGM device in the populations with nocturnal
hypoglycemia, hypoglycemic unawareness where the
usefulness of SMBG is limited.
Type 2 Diabetic Adults
It was found that CGM can be a useful tool to reduce
HbA1c level in type 2 diabetes adults. Although no het-
erogeneity was detected (I2 = 0%), there were some varia-
tions among the included studies in terms of study
quality, types of data presentation (retrospective and
real-time), frequency and duration of CGM use, inter-
vention used by the participants. Among four studies in-
cluded, two studies used retrospective CGM [32,33]
whereas other two studies used real-time CGM [31,34].
The frequency of CGM use differed greatly from trial to
trial, making it difficult to suggest which one is the most
appropriate frequency of CGM use. Generally, factors toversus SMBG in T2DM adults.
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include the conditions of patients, i.e. whether their gly-
cemia are poorly controlled or well controlled, and to
what extent they are vulnerable to hypoglycemia. Partici-
pants were treated with either oral hypoglycemic agents
only [33], prandial insulin [34] or both insulin and oral
hypoglycemic agents [31,32].
According to 2006 American Diabetes Association’s
recommendation, SMBG is regarded as an essential
aspect of diabetes management in insulin-treated pa-
tients and a desirable aspect in non-insulin treated pa-
tients with diabetes [45]. Although, the effectiveness of
SMBG in T2DM patients who do not use insulin had
been provided in some meta-analyses, SMBG is not
recommended yet. High risk of hypoglycemia can be
predisposed by the use of insulin, whereas oral agents
particularly metformin, thiazolidinediones, and DPP-4
inhibitors, are not prone to result in hypoglycemia.
Moreover, SMBG data or CGM data are generally used
to adjust insulin dose. Therefore, in non-insulin treated
T2DM, the value of SMBG and CGM previously seems
to be limited. In our review, participants in the study by
Ehrhardt et al. [34] did not use prandial insulin and par-
ticipants in the study by Allen et al. [33] did not use any
type of insulin at all. These two studies reported the sig-
nificant reduction in HbA1c in favor of CGM group.
This may be because CGM data can provide benefit to
lifestyle intervention other than adjusting insulin ther-
apy. In the study by Allen et al. [33], CGM device was
used as a counseling tool in evaluating the effect of
physical activity on glycemic control and in the study by
Ehrhardt et al. [34], patients were allowed to manage
their lifestyle based on CGM data. In agreement with
the result, CGM use in non-insulin treated T2DM may
be beneficial. It is noted that patients enrolled in individ-
ual studies had baseline HbA1c > 8%. Thus, CGM de-
vices may be a useful tool in poorly controlled T2DM
patients.
When the effectiveness of the r-CGM and RT-CGM com-
pared with SMBG were analyzed separately in T2DM pa-
tients, only RT-CGM devices improved glycemic control
[mean difference -0.27% (95%CI-0.34 to -0.19)]. One sys-
tematic review concluded that RT-CGM may be more ef-
fective than r-CGM in type 1 diabetes [39]. However, in type
2 diabetes, whether retrospective CGM or real-time CGM
provides superior benefit in lowering HbA1c level compared
with SMBG is not known yet. In our meta-analysis, two
studies used RT-CGM (Yoo et al. and Ehrhardt et al.)
[31,34] and two studies analyzed data in a retrospective
manner (Allen et al. and Cosson et al.) [32,33]. Both RT-
CGM studies and one r-CGM study provided significant dif-
ference in lowering HbA1c level by CGM compared with
SMBG. However, there is a confounding factor in the study
used r-CGM. This r-CGM study was performed to test therole of CGM feedback in physical activity counseling. There-
fore, all participants in the study were in physical activity
program and these participants were educated about the
benefit of physical activity using individual CGM graph or
profile at the end of study. As a result, it is difficult to say
that lowering HbA1c level was due to CGM device since
there was an impact of physical activity on HbA1c level.
Therefore, it may be possible that positive effect in our
meta-analysis was contributed merely by RT-CGM. Unfor-
tunately, subgroup analysis for quantitative examination of
the effect of r-CGM and RT-CGM cannot be performed
since the number of studies was too small.
In addition to pharmacological intervention, lifestyle inter-
vention is already accepted as an important aspect in the
management of type 2 diabetes. Patients with lifestyle inter-
vention experience significant improvement in blood glu-
cose and lipid profile after one year compared with those
without this intervention, supporting the value of lifestyle
intervention in T2DM management [46]. Continuous glu-
cose monitoring can provide glucose information promptly
to adjust the dosages of medication, and/or to manage the
dietary or exercise regimen, which could lead to better life-
style for diabetes patients. In other words, the glycemic
values from CGM devices allow care provider or patient to
encounter the noticeable effects of meals and exercise on
glycemic level and to manage lifestyle skills that results in
better glycemic control. Moreover, from the glycemic values
displayed by CGM devices, patients can be easily educated
about the effects of their medication and lifestyle on dia-
betes. A study testing the effects of counseling intervention
of physical activity and using continuous glucose monitoring
system feedback suggested that counseling T2DM patients
with CGM feedback may improve physical activity level and,
as a result, diabetes-related complications could be reduced
[33]. Therefore, with the help of continuous glucose moni-
toring, not only pharmacological intervention can be ad-
justed, but non-pharmacological intervention can also be
promoted.
There were some limitations in the meta-analysis of type
2 diabetes. We did not search for unpublished trials. Thus
there was a possibility of missing relevant data. However, no
publication bias was detected. The average baseline HbA1c
of participants from all studies was above 8%. Therefore, the
routine use of CGM in patients with uncontrolled T2DM
may provide benefit and deserves consideration. More ran-
domized trials with adequate sample sized are needed for
CGM use in type 2 diabetes population. In addition, further
studies are suggested to focus on the frequency and duration
of RT-CGM use to achieve the legacy effects.
Conclusion
Type 1 diabetic pediatrics
The available evidence from this meta-analysis suggests
that CGM use was no more effective than SMBG in
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the results of subgroup analyses showed that RT-CGM
can be more effective than SMBG in reducing HbA1c.
In contrast, r-CGM was no better than SMBG in T1DM
pediatric population. Therefore, RT-CGM devices can be
an effective tool in Type 1 diabetic pediatrics population.
Type 2 diabetic adults
Our results suggest that the effect of CGM use in lower-
ing HbA1c level was superior to SMBG for type 2 dia-
betes adults. Since the average baseline HbA1c of
participants from all studies was above 8%, CGM device
can be an effective tool in patients with uncontrolled
T2DM. However, the comprehensive randomized con-
trolled trial need to be established in order to address
the long term benefit of CGM.
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